Interethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 21, Issue 2, 1996, Pages 129-138

  Llerena, A ^a   Cobaleda, J ^a   Martinez C ^a   Benitez J ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

CYP2D6; Debrisoquine; Gender; Pharmacogenetics; Smoking

Indexed keywords

ALCOHOL; CAFFEINE; DEBRISOQUINE; HALOPERIDOL; ORAL CONTRACEPTIVE AGENT;

ADULT; CAUCASIAN; CHINESE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN EXPERIMENT; LUTEAL PHASE; MALE; MENSTRUAL CYCLE; NORMAL HUMAN; OVULATION; PEDIGREE; PHARMACOGENETICS; PHENOTYPE; SEX DIFFERENCE; SMOKING CESSATION; TOBACCO;

EID: 0030017515     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190261     Document Type: Conference Paper

References (54)

1. Wood J.J., Zhou H.H. (1991) : Ethnic differences in drug disposition and responsiveness. Clin. Pharmacokinet., 20, 350-373.
2. Kalow W. (1992) : Pharmacoanthropology and the genetics of drug metabolism. In: Kalow W.(Ed.) Pharmacogenetics of Drug Metabolism. New York, Pergamon, pp. 865-877.
3. Kalow W., Bertilsson L. (1994) : Interethnic factors affecting drug response. Adv. Drug Res., 25, 1-53.
4. Bertilsson L. (1995) : Geographical/interracial differences in polymorphic drug oxidation. Clin. Pharmacokinet., 29, 129-209.
5. Kalow W. (1991) : Interethnic variation of drug metabolism. Trends Pharmacol. Sci., 12, 102-107.
6. Mahgoub A., Idle J.R., Dring L.G.. Lancaster R., Smith R.L. (1977) : Polymorphic hydroxylation of debrisoquine in man. Lancet, 2, 584-586.
7. Eichelbaum M., Spambrucker N., Steincke B., Dengler H.J. (1979) : Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol., 16, 183-187.
8. Wedlund P.J., Aslanian, W.S., McAllister C.B., Wilkinson G.R., Branch R.A. (1984) : Mcphenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism. Clin. Pharmacol. Ther., 36, 773-780.
9. Evans D.A.P., Mahgoub A., Sloan T.P., Idle J.R., Smith R.L. (1980) : A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet, 17, 102-105.
10. Henthorn T.K., Benítez J., Avram M.J., et al. (1989) : Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distribution analysis. Clin. Pharmacol. Ther., 45, 328-333.
11. Brøsen K., Gram L.F. (1989) : Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol., 36, 537-349.
12. Dahl M.L., Bertilsson L. (1993) : Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics, 3, 61-70
13. Steiner E., Iselius L., Alván G., Lindsten J., Sjöqvist F. (1985) : A family and population study of the genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin. Pharmacol. Ther., 38, 394-401.
14. Zanger U.M., Vilbois F., Hardwick J.P., Meyer U.A. (1988) : Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry, 27, 5447-5454.
15. Eichelbaum M., Baur M.P., Dengler H.J., et al.(1987) : Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br. J. Clin. Pharmacol., 23, 455-458.
16. Dahl M.L., Bertilsson L., Chang M., et al. (1995) : Genetic contribution to interethnic variations in drug metabolism In: Alván G., Balant L.P., Bechlel P.R., Boobis A.R., Gram L.F., Paintaud G., Pithan K. (Eds) COST B1 European Cooperation in the Field of Scientific and Technical Research. Brussels-Luxembourg, European Commission, 94-111.
17. Goldstein J.A., de Morais S.M.F. (1994) : Biochemistry and molecular biology of the human CYP2D family. Pharmacogenetics, 4, 285-299.
18. Alván G., Bechtel P., Iselius L., Gundert-Remy U. (1990) : The hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol., 39, 533-537.
19. Benítez J., LLerena A., Cobaleda J. (1988) : Debrisoquin oxidation polymorphism in a Spanish population. Clin. Pharmacol Ther., 44, 74-77.
20. Johansson I., Lundqvist E., Bertilsson L., Dahl M.L., Sjóqvist F., Ingelman-Sundberg M. (1993) : Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA, 90, 11825-11829
21. Agúndez J.A.G., Ledesma M.C., Ladero J.M., Benítez J. (1994) . Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin. Pharmacol. Ther., 57, 265-269.
22. Bertilsson L., Lou Y.Q., Du Y.L., et al. (1992) : Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and mephenytoin. Clin. Pharmacol. Ther., 38, 402-408.
23. Reviriego J., Bertilsson L., Carrillo J.A., LLerena A., Valdivieiso M.J., Benítez J. (1993) : Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared with other Caucasian populations. Eur. J. Clin. Pharmacol., 44, 593-595.
24. LLerena A., Valdivielso M.J., Benítez J., Bertilsson L. (1993) : Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes. Pharmacol. Toxicol., 73, 46-48.
25. Vesell E. (1977) : Genetic and environmental factors affecting drug disposition in man. Clin. Pharmacol. Ther., 22, 659-679.
26. Wilson K. (1984) : Sex-related differences in drug disposition in man. Clin. Pharmacokinet., 9, 89-202.
27. Eichelbaum M., Mineshita S., Ohnhaus E.E., Zekorn C. (1986) : The influence of enzyme induction on polymorphic sparteine oxidation. Br. J. Clin. Pharmacol., 22, 49-53.
28. Bock K.W., Schrenk D., Forster A., et al. (1994) : The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyl-transferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics, 4, 209-218.
29. Benítez J., LLerena A., Cobaleda J., Martínez C. (1987) : Posible inducción del metabolismo de debrisoquina por etanol. Rev. Esp. Farm. Clin. Exp., 3, 230.
30. Benítez J., LLerena A., Cobaleda J. (1987) : Sex dependent effects of smoking on debrisoquine oxidation in man. 7th Symposium on Microsomes and Drug Oxidation. Adelaide.
31. LLerena A., Puerto A.M., Martínez C., et al. (1989) : Debrisoquine oxidation phenotype after ovariotomy. Eur. J. Clin. Pharmacol., 36, A198.
32. Högsted S., Lindberg B.S., Peng D.R., Regardh C.G., Rane A. (1985) : Pregnancy-induced increase in metoprolol metabolism. Clin. Pharmacol. Ther., 37, 688-692.
33. Kallio J., Lindberg R., Huupponen R., Iisalo E. (1988) : Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on metabolic ratio. Br. J. Clin. Pharmacol., 26, 791-795.
34. Ohnhaus E.E. (1987) : The effect of ethanol on sparteine metabolism in man. Clin. Pharmacol. Ther., 41, 246.
35. Dawson G.W., Vestal R.E. (1982): Smoking and drug metabolism. Pharmacol. Ther., 15, 207-221.
36. Lennard M.S , Jackson P.R., Freestone S., Tucker G.T. Ramsay L.E., Woods H.F. (1984) : The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br. J. Clin. Pharmacol., 17, 679-685.
37. Cholerton S., Arpanahi A., McCracken N., et al. (1994) : Poor metabolisers of nicotine and CYP2D6 metabolism. Lancet, 343, 62-63.
38. Straka R.J., Shawn R.H., Walker P.F. (1995) : Comparison of the prevalence of the poor metaboliser phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. Clin. Pharmacol. Ther., 58, 29-34.
39. Brown C.R., Jacob III P., Wilson M., Benowitz N.L. (1988) : Changes in rate and pattern of caffeine metabolism after cigarette abstinence. Clin. Pharmacol. Ther., 43, 488-491.
40. Fiset C., LeBel M. (1990) : Influence of menstrual cycle on the absorption and elimination of D-xylose. Clin. Pharmacol. Ther., 1990, 48, 529-536.
41. Pepper J.M., Lennard M.S., Tucker G.T., Woods H.F. (1991) : Effect of steroids on the cytochrome P450D6-catalysed metabolism of metoprolol. Pharmacogenetics, 1, 119-122.
42. Froemming J.S., Lam F.Y.W., Jann M.W., Davis C.M. (1989) : Pharmacokinetics of haloperidol. Clin. Phannacokinet., 17, 396-423.
43. Syvälahti E.K.G., Lindberg R., Kallio J., de Vocht M. (1986) : Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br. J. Clin. Pharmacol., 22, 89-92.
44. Benítez J., Piñas B., García M.A., Martínez C., LLerena A., Cobaleda J. (1989) : Debrisoquine oxidation phenotype in psychiatric patients. In: Dahl S.G., Gram L.F. (Eds) Clinical Pharmacology in Psychiatry. Berlin, Springer-Verlag, pp. 206-210.
45. LLerena A., Dahl M.L., Ekqvist B., Bertilsson L. (1992) : Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit., 14, 92-97.
46. LLerena A., Alm C., Dahl M.L., Ekqvist B., Bertilsson L. (1992) : Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther. Drug Monit., 14, 261-264.
47. Jann M.W., Chang W.H., Davis C.M., et al. (1989) : Haloperidol and reduced haloperidol plasma, levels in Chinese vs. non-Chinese psychiatric patients. Psychiatry Res., 30, 45-52.
48. Lin K.M., Poland R.E., Lau J.K., Rubin R.T. (1988) : Haloperidol and prolactin concentrations in Asians and Caucasians. J. Clin. Psychopharmacol., 8, 195-201.
49. Potkin S.G., Shen Y., Pardes H., et al. (1984) : Haloperidol concentrations elevated in Chinese patients. Psychiatry Res., 12, 167-172.
50. Bertilsson L., Alm C., de las Carreras C., Widén J., Edman G., Schalling D. (1989) : Debrisoqusne hydroxylation polymorphism and personality. Lancet, 2, 555.
51. LLerena A., Edman G., Cobaleda J., Benítez J., Schalling D., Bertilsson L. (1993) : Relationship between personality and debrisoquine relation capacity. Suggestions for an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psych. Scand., 87, 23-28.
52. LLerena A., Cobaleda J., Benítez J. (1989) : Debrisoquine hydroxylation phenotypes in healthy volunteers. Lancet, 2, 1398.
53. Brøsen K., Sindrup S.H., Skjelbo E., Nielsen K.K., Nørremark P., Gram L.F. (1993) : Role of genetic polymorphism in psychopharmacology -an update. In: Dahl S.G., Gram L.F., Balant L.P., Meltzer H.Y. (Eds) Clinical Pharmacology in Psychiatry. Berlin, Springer-Verlag, pp. 199-211.
54. 3H] GBR-12935 binding proteins. Arch. Biochem. Biophys., 276, 424-432.